Novo Nordisk Taps Omnicom to Lead US Marketing for Ozempic and Wegovy
Novo Nordisk has a new media partner. The drugmaker just named Omnicom as its agency of record for US…
-
-
Why Bank of America Now Spends $250 Million a Year on Weight-Loss Drugs
Bank of America has quietly built up one of the biggest corporate GLP-1 medication bills in the country. The…
-
New Research Suggests GLP-1 Drugs Could Help Reduce Aggressive Tendencies
Glucagon-like peptide-1 receptor agonists have completely changed how doctors manage type 2 diabetes and obesity. Daily medications like Ozempic,…
-
Medicare Is Opening the Door Wider for Eli Lilly’s Weight Loss and Diabetes Drugs
Eli Lilly’s latest earnings report caught the attention of analysts and patients alike. The drugmaker reported $19.8 billion in…
-
Next-Generation GLP-1 Drugs Deliver Surgical-Level Weight Loss, Raising Questions About Systemic Safety
Retatrutide acts as a new kind of experimental medicine. This drug helped people lose over 28 percent of their…
-
Health Canada Clears First Generic Semaglutide, Signaling New Competitive Phase for GLP-1 Market
The national health agency recently approved the first generic version of semaglutide. This important decision ends the exclusive market…
-
Eli Lilly’s Foundayo Joins TrumpRx Platform Following Expedited FDA Approval
The Food and Drug Administration approved Eli Lilly’s once daily weight loss pill, Foundayo, on April 1, 2026. This…
